- Email: [email protected]
Join us at The Lancet Clinic
Comment
of Neurology, University of Michigan; University of Michigan Udall Center for Excellence in Parkinson Disease Research; Michigan Alzheimer Disease Center; and 5023 Biomedical Science Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA [email protected] I am a member of the Data Safety and Monitoring Boards for PRIDE-HD and LEGATO-HD trials (ICON/Teva) and an upcoming trial of anti-sense oligonucleotides in Huntington’s disease (ISIS). My work is supported by P50 NS091856, R56 NS082941, and R21 NS088302. 1 2
3
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington’s disease. Lancet Neurol 2015; 14: 1135–42. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington’s disease gene in brain and non-neural tissues. Nat Genet 1993; 5: 259–65. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–83.
4
5 6
7 8
Jafar-Nejad P, Ward CS, Richman R, Orr HT, Zogbhi HY. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Nat Acad Sci USA 2011; 208: 2143–47. Aylward EH. Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington’s disease. Mov Disord 2014; 29: 1429–33. Niccolini F, Haider S, Marques TR, et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain 2015; published online July 21. DOI:10.1093/brain/awv214. Paul DB, Brosco JP. The PKU paradox. Baltimore, MD: Johns Hopkins University Press, 2013. Albin RL, Burke JF. Potential trade-offs in treatment of premanifest Huntington’s disease. Mov Disord 2015; published online July 14. DOI:10.1002/mds.26318.
Join us at The Lancet Clinic
Published Online October 5, 2015 http://dx.doi.org/10.1016/ S1474-4422(15)00252-5 For The Lancet Clinic see http://www.thelancet.com/clinic
For The Lancet Commission on liver disease in the UK see http://www.thelancet.com/ commissions/crisis-of-liverdisease-in-the-uk For The Lancet Liver Campaign see http://www.thelancet.com/ campaigns/liver For The Lancet Oncology/ The Lancet Cancer Campaign see http://www.thelancet.com/ campaigns/cancer
1072
On Oct 5, 2015, we launch the first 45 disease-specific pages of a major new online initiative involving all Lancet journals that will bring together an overview Seminar and relevant Reviews, Clinical Series, Commissions, research, Case Reports, and Clinical Pictures. Over the next 18 months or so when The Lancet Clinic is complete, there will be online pages for 135 diseases, which we have identified by a combination of global burden of disease data and clinical practice needs. We hope that The Lancet Clinic will help practising doctors make better informed decisions that ultimately lead to better lives of people worldwide, and help others who want to educate or update themselves keep abreast of the evolving evidence base. Importantly, these pages will be updated at regular intervals. The authors of newly commissioned Seminars have agreed to provide regular summaries of important new evidence for 4 years. Individual clinical editors will pull together newly published material from across the Lancet journals and post links to these on the page regularly. In addition, we are continuing our regular editorial policies of commissioning more specialised Clinical Reviews and Series across The Lancet Group to provide a more focused and in-depth assessment for key diseases. And beyond providing knowledge and information, we want to encourage academic and practising clinicians to use this knowledge for advocacy and change. In 2014, The Lancet published the first Clinical Commission on liver disease in the UK and in February, 2015, we launched our first
Clinical Campaign based on this Commission. A Cancer Campaign as a joint effort between The Lancet and The Lancet Oncology followed in April. Clinical Campaigns aim to effect change based on data, knowledge, and expert interpretation in partnership with others. Further Clinical Commissions on asthma, hypertension, dementia, tuberculosis, traumatic brain injury, psychotherapy, chronic obstructive pulmonary disease, and others are underway across all Lancet journals. With these Clinical Commissions and Campaigns, we hope to extend our goal to publish the best science for better lives to being an active partner in using this science for actual change. Commissions and Campaigns will be part of the disease pages to encourage engagement and actions. The Lancet Clinic invites you to be part of this endeavour. *Sabine Kleinert, Richard Horton, Elena Becker-Barroso, Niall Boyce, David Collingridge, Justine Davies, Emma Grainger, Peter Hayward, John McConnell, Zoë Mullan, Lan-Lan Smith The Lancet, London EC2Y 5AS, UK (SK, RH); The Lancet Neurology, London, UK (EB-B); The Lancet Psychiatry, London, UK (NB); The Lancet Oncology, London, UK (DC); The Lancet Diabetes & Endocrinology, London, UK (JD); The Lancet Respiratory Medicine, London, UK (EG); The Lancet HIV, London, UK (PH); The Lancet Infectious Diseases, London, UK (JM); The Lancet Global Health, London, UK (ZM); and The Lancet Haematology, London, UK (L-LS) [email protected] Copyright © Kleinert et al. Open Access article distributed under the terms of CC BY.
www.thelancet.com/neurology Vol 14 November 2015
of Neurology, University of Michigan; University of Michigan Udall Center for Excellence in Parkinson Disease Research; Michigan Alzheimer Disease Center; and 5023 Biomedical Science Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA [email protected] I am a member of the Data Safety and Monitoring Boards for PRIDE-HD and LEGATO-HD trials (ICON/Teva) and an upcoming trial of anti-sense oligonucleotides in Huntington’s disease (ISIS). My work is supported by P50 NS091856, R56 NS082941, and R21 NS088302. 1 2
3
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington’s disease. Lancet Neurol 2015; 14: 1135–42. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington’s disease gene in brain and non-neural tissues. Nat Genet 1993; 5: 259–65. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–83.
4
5 6
7 8
Jafar-Nejad P, Ward CS, Richman R, Orr HT, Zogbhi HY. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Nat Acad Sci USA 2011; 208: 2143–47. Aylward EH. Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington’s disease. Mov Disord 2014; 29: 1429–33. Niccolini F, Haider S, Marques TR, et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain 2015; published online July 21. DOI:10.1093/brain/awv214. Paul DB, Brosco JP. The PKU paradox. Baltimore, MD: Johns Hopkins University Press, 2013. Albin RL, Burke JF. Potential trade-offs in treatment of premanifest Huntington’s disease. Mov Disord 2015; published online July 14. DOI:10.1002/mds.26318.
Join us at The Lancet Clinic
Published Online October 5, 2015 http://dx.doi.org/10.1016/ S1474-4422(15)00252-5 For The Lancet Clinic see http://www.thelancet.com/clinic
For The Lancet Commission on liver disease in the UK see http://www.thelancet.com/ commissions/crisis-of-liverdisease-in-the-uk For The Lancet Liver Campaign see http://www.thelancet.com/ campaigns/liver For The Lancet Oncology/ The Lancet Cancer Campaign see http://www.thelancet.com/ campaigns/cancer
1072
On Oct 5, 2015, we launch the first 45 disease-specific pages of a major new online initiative involving all Lancet journals that will bring together an overview Seminar and relevant Reviews, Clinical Series, Commissions, research, Case Reports, and Clinical Pictures. Over the next 18 months or so when The Lancet Clinic is complete, there will be online pages for 135 diseases, which we have identified by a combination of global burden of disease data and clinical practice needs. We hope that The Lancet Clinic will help practising doctors make better informed decisions that ultimately lead to better lives of people worldwide, and help others who want to educate or update themselves keep abreast of the evolving evidence base. Importantly, these pages will be updated at regular intervals. The authors of newly commissioned Seminars have agreed to provide regular summaries of important new evidence for 4 years. Individual clinical editors will pull together newly published material from across the Lancet journals and post links to these on the page regularly. In addition, we are continuing our regular editorial policies of commissioning more specialised Clinical Reviews and Series across The Lancet Group to provide a more focused and in-depth assessment for key diseases. And beyond providing knowledge and information, we want to encourage academic and practising clinicians to use this knowledge for advocacy and change. In 2014, The Lancet published the first Clinical Commission on liver disease in the UK and in February, 2015, we launched our first
Clinical Campaign based on this Commission. A Cancer Campaign as a joint effort between The Lancet and The Lancet Oncology followed in April. Clinical Campaigns aim to effect change based on data, knowledge, and expert interpretation in partnership with others. Further Clinical Commissions on asthma, hypertension, dementia, tuberculosis, traumatic brain injury, psychotherapy, chronic obstructive pulmonary disease, and others are underway across all Lancet journals. With these Clinical Commissions and Campaigns, we hope to extend our goal to publish the best science for better lives to being an active partner in using this science for actual change. Commissions and Campaigns will be part of the disease pages to encourage engagement and actions. The Lancet Clinic invites you to be part of this endeavour. *Sabine Kleinert, Richard Horton, Elena Becker-Barroso, Niall Boyce, David Collingridge, Justine Davies, Emma Grainger, Peter Hayward, John McConnell, Zoë Mullan, Lan-Lan Smith The Lancet, London EC2Y 5AS, UK (SK, RH); The Lancet Neurology, London, UK (EB-B); The Lancet Psychiatry, London, UK (NB); The Lancet Oncology, London, UK (DC); The Lancet Diabetes & Endocrinology, London, UK (JD); The Lancet Respiratory Medicine, London, UK (EG); The Lancet HIV, London, UK (PH); The Lancet Infectious Diseases, London, UK (JM); The Lancet Global Health, London, UK (ZM); and The Lancet Haematology, London, UK (L-LS) [email protected] Copyright © Kleinert et al. Open Access article distributed under the terms of CC BY.
www.thelancet.com/neurology Vol 14 November 2015